# Liraglutide

> FDA-approved daily GLP-1 receptor agonist.

Source: https://peptides.cafe/peptide/liraglutide
Category: Metabolic · Incretin
Tag: Weight loss · Diabetes

## Mechanism
A daily GLP-1 receptor agonist with a fatty-acid side chain that enables albumin binding and ~13-hour half-life. Mechanism mirrors semaglutide at shorter duration: enhanced glucose-dependent insulin release, slowed gastric emptying, and central appetite suppression.

## Research areas
- Type 2 diabetes (Victoza)
- Chronic weight management (Saxenda)
- Cardiovascular risk reduction in T2D

## Common research protocols
- Daily subcutaneous clinical use: Stepwise dose escalation in approved indications.

## Study summaries
- "Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER)" — New England Journal of Medicine (2016): Significant reduction in major adverse cardiovascular events vs placebo.

## Considerations
- FDA-approved; requires prescription and physician oversight.
- GI side effects, pancreatitis risk, gallbladder events.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.